In former guidelines, it was acceptable for SABA monotherapy to be used for patients with mild, intermittent asthma. After the NRAD report, it was established that SABA monotherapy is not appropriate for any patients with Asthma.

And the reason – without steroids, airway inflammation build and builds, until an inevitable exacerbation. Short acting bronchodilators do not dampen inflammation.

In this episode, we explore the current approach to Asthma Management in clinical practice, including:

1. Empower patients to take control of their asthma
2. Escalation and de-escalation of inhaled therapies
3. Ongoing poor control of asthma; when to refer to secondary care